The work in this study focused on the impact of disrupting Slc6a14 on the CF phenotype in the mouse intestine, because this phenotype has been well described by multiple laboratories (Canale-Zambrano et al., 2007; Rozmahel et al., 1996; Scholte et al., 2004; van Doorninck et al., 1995; Wilke et al., 2011). Here, SLC6A14 is linked to cystic fibrosis.